NUVB
Price
$6.07
Change
-$0.21 (-3.34%)
Updated
Sep 11 closing price
Capitalization
2.13B
60 days until earnings call
Intraday BUY SELL Signals
SVRA
Price
$5.30
Change
-$0.02 (-0.38%)
Updated
Sep 11 closing price
Capitalization
1.09B
54 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NUVB vs SVRA

NUVB vs SVRA Comparison Chart in %
View a ticker or compare two or three
VS
NUVB vs. SVRA commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVB is a Hold and SVRA is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVB($2.13B) has a higher market cap than SVRA($1.09B). SVRA YTD gains are higher at: -12.106 vs. NUVB (-32.254). NUVB has higher annual earnings (EBITDA): -121.01M vs. SVRA (-142.66M). NUVB has more cash in the bank: 661M vs. SVRA (173M). SVRA has less debt than NUVB: SVRA (30.4M) vs NUVB (252M). NUVB has higher revenues than SVRA: NUVB (170M) vs SVRA (0).
NUVBSVRANUVB / SVRA
Capitalization2.13B1.09B196%
EBITDA-121.01M-142.66M85%
Gain YTD-32.254-12.106266%
P/E RatioN/AN/A-
Revenue170M0-
Total Cash661M173M382%
Total Debt252M30.4M829%
FUNDAMENTALS RATINGS
NUVB vs SVRA: Fundamental Ratings
NUVB
SVRA
OUTLOOK RATING
1..100
8273
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
61
Fair valued
PROFIT vs RISK RATING
1..100
10044
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
3849
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
328

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NUVB's Valuation (47) in the null industry is in the same range as SVRA (61) in the Biotechnology industry. This means that NUVB’s stock grew similarly to SVRA’s over the last 12 months.

SVRA's Profit vs Risk Rating (44) in the Biotechnology industry is somewhat better than the same rating for NUVB (100) in the null industry. This means that SVRA’s stock grew somewhat faster than NUVB’s over the last 12 months.

NUVB's SMR Rating (98) in the null industry is in the same range as SVRA (99) in the Biotechnology industry. This means that NUVB’s stock grew similarly to SVRA’s over the last 12 months.

NUVB's Price Growth Rating (38) in the null industry is in the same range as SVRA (49) in the Biotechnology industry. This means that NUVB’s stock grew similarly to SVRA’s over the last 12 months.

NUVB's P/E Growth Rating (100) in the null industry is in the same range as SVRA (100) in the Biotechnology industry. This means that NUVB’s stock grew similarly to SVRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NUVBSVRA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 26 days ago
82%
Bullish Trend 18 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
73%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (NUVB: $6.07 vs. SVRA: $5.30)
Brand notoriety: NUVB and SVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVB: 76% vs. SVRA: 62%
Market capitalization -- NUVB: $2.13B vs. SVRA: $1.09B
NUVB [@Biotechnology] is valued at $2.13B. SVRA’s [@Biotechnology] market capitalization is $1.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVB’s FA Score shows that 0 FA rating(s) are green while SVRA’s FA Score has 0 green FA rating(s).

  • NUVB’s FA Score: 0 green, 5 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, SVRA is a better buy in the long-term than NUVB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVB’s TA Score shows that 5 TA indicator(s) are bullish while SVRA’s TA Score has 2 bullish TA indicator(s).

  • NUVB’s TA Score: 5 bullish, 4 bearish.
  • SVRA’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, NUVB is a better buy in the short-term than SVRA.

Price Growth

NUVB (@Biotechnology) experienced а -10.87% price change this week, while SVRA (@Biotechnology) price change was -1.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

NUVB is expected to report earnings on Nov 11, 2026.

SVRA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
NUVB
Daily Signal:
Gain/Loss:
SVRA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GEM51.830.65
+1.27%
Goldman Sachs ActiveBeta® EMkts Eq ETF
MSFO12.130.11
+0.92%
YieldMax MSFT Option Income Strategy ETF
DSEP48.680.15
+0.31%
FT Vest US Equity Dp Bffr ETF Sep
DEFR26.360.03
+0.13%
Aptus Deferred Income ETF
YCS51.17-0.40
-0.77%
ProShares UltraShort Yen

SVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with FDMT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then FDMT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
-0.38%
FDMT - SVRA
45%
Loosely correlated
-2.37%
MGTX - SVRA
43%
Loosely correlated
-0.47%
NUVB - SVRA
42%
Loosely correlated
-3.34%
NRIX - SVRA
41%
Loosely correlated
-2.75%
PHVS - SVRA
41%
Loosely correlated
+1.36%
More